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Abstract
Background: Pre-eclampsia (PE) is related to an impaired endothelial function. Endothelial dysfunction accounts for
altered vascular reactivity, activation of the coagulation cascade and loss of vascular integrity. Impaired endothelial
function originates from production of inflammatory and cytotoxic factors by the ischemic placenta and results in
systemic oxidative stress (OS) and an altered bioavailability of nitric oxide (•NO). The free radical •NO, is an endogenous
endothelium-derived relaxing factor influencing endothelial function. In placental circulation, endothelial release of •NO
dilates the fetal placental vascular bed, ensuring feto-maternal exchange. The Endopreg study was designed to
evaluate in vivo endothelial function and to quantify in vitro OS in normal and pre-eclamptic pregnancies.
Methods/design: The study is divided into two arms, a prospective longitudinal study and a matched case control
study. In the longitudinal study, pregnant patients ≥18 years old with a singleton pregnancy will be followed throughout
pregnancy and until 6 months post-partum. In the case control study, cases with PE will be compared to matched
normotensive pregnant women. Maternal blood concentration of superoxide (O2•) and placental concentration of •NO
will be determined using EPR (electron paramagnetic resonance). Endothelial function and arterial stiffness will be
evaluated using respectively Peripheral Arterial Tonometry (PAT), Flow-Mediated Dilatation (FMD) and applanation
tonometry. Placental expression of eNOS (endothelial NOS) will be determined using immune-histochemical staining.
Target recruitment will be 110 patients for the longitudinal study and 90 patients in the case-control study.
Discussion: The results of Endopreg will provide longitudinal information on in vivo endothelial function and in vitro OS
during normal pregnancy and PE. Adoption of these vascular tests in clinical practice potentially predicts patients at risk
to develop cardiovascular events later in life after PE pregnancies. •NO, O2•
− and eNOS measurements provide further
inside in the pathophysiology of PE.
Trial registration: This trial has been registered on clinicaltrials.gov. ClinicalTrials.gov Identifier: NCT02603913. Registered
October 2015.
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Background
Pre-eclampsia (PE) is a potentially life-threatening preg-
nancy related vasculopathy characterized by hypertension
and proteinuria. PE results in high morbi-mortality for
both mother and her unborn child. Between five and 10 %
of pregnancies are complicated by hypertensive disorders
and worldwide the incidence of PE has increased by 25%
in the past two decades [1].
In normal pregnancy vascular remodelling of the mater-
nal uterine spiral arteries occurs. Trophoblast cells invade
the spiral arterioles within the first 12 weeks of pregnancy
and replace the muscular wall of the vessels converting
them into wide bore, low resistance, large capacity vessels,
a process normally completed by 20 weeks gestation [2].
The free radical nitric oxide (•NO) is an important medi-
ator of the placentation process. •NO is an endogenous
endothelium-derived relaxing factor influencing endothelial
function. Under physiologic conditions, endothelial release
of •NO in the placental circulation dilates the fetal placental
vascular bed, ensuring feto-maternal exchange [3]. •NO is
formed out of L-Arginine by NOS (Nitric Oxide Synthase).
This reaction is regulated by VEGF (Vascular endothelial
growth factor), an endothelial mitogen that has an import-
ant function in the proliferation of endothelial cells and in
angiogenesis. VEGF stimulates eNOS (endothelial NOS)
and induces therefore •NO production [4]. In an oxidative
environment, the lack of NOS-stabilizing factors results in
NOS-uncoupling. NOS-coupling causes a shift from •NO
production to superoxide (O2•
−) production which main-
tains an oxidative setting.
The pathogenesis of generalized endothelial dysfunction
is well known in PE and is subdivided into two phases.
The first phase exists of a poor trophoblast invasion of the
spiral arteries during the placentation process, causing
failure to transform the placental bed arteries from high to
low resistance vessels. This results in local ischemia, re-
perfusion damage and oxidative stress (OS). The local
damage activates the second phase where disturbed pro-
duction of angiogenic and anti-angiogenic factors (placen-
tal growth factor (PlGF) and soluble fms-like tyrosine
kinase 1 (sFlt-1), respectively) results in systemic inflam-
mation, endothelial activation, systemic OS and altered
endothelial •NO production [5, 6]. When this vascular
endothelial activation and dysfunction occurs at the level
of liver, kidney, brain and placenta, the clinical presenta-
tion of PE arises [7].
In the past, PE has been divided in two different entities;
angiogenic or placental PE (formerly called early onset,
before 34 weeks) and non-angiogenic or maternal PE
(formerly called late onset, after 34 weeks) [8]. Impaired
placentation and endothelial dysfunction have been de-
scribed in placental PE, whereas pre-existing maternal car-
diovascular risk factors (essential hypertension, high BMI,
diabetes, renal disease,..) usually precede maternal PE.
This description however oversimplifies and overstates re-
cent existing findings. Maternal risk factors can precede
early onset PE as well as abnormal concentrations of pla-
cental angiogenic factors are found in late onset PE [6].
Fetal growth restriction and endothelial dysfunction
caused by systemic inflammation are usually described in
placental PE, nevertheless they are common in late onset
PE. It is therefore more accurate to state that both mater-
nal and placental factors contribute to PE and research
should focus on classifications based on pathophysiologic
processes, for instance endothelial and vascular dysfunc-
tion and amount of systemic inflammation and OS [9, 10].
In normal pregnancy, placental OS is present during
all three trimesters and is necessary to obtain normal
cell function, including activation of redox-sensitive
transcription factors and activation of protein kinases
[11–15]. Although OS is a common necessary feature of
normal pregnancy, persistent OS gives rise to different
disease-states, such as PE [13, 15–17]. Although consid-
erable research has been devoted to OS in PE [13–15],
less attention has been paid to the evolution of OS dur-
ing the course of normal pregnancy. Little research has
described an increase in •NO concentration with gesta-
tional age, suggesting an important role for •NO in the
cardiovascular changes of normal pregnancy [3].
Recent literature has elucidated that PE is an import-
ant risk factor for cardiovascular disease in later life. Bel-
lamy et al. and McDonald et al. describe a 3-fold risk for
hypertension and a 2-fold risk of ischemic heart disease
and stroke in women with a history of PE [18–21].
Women with hypertensive disorders during pregnancy
also have a greater risk of chronic kidney disease and
end-stage renal disease [22, 23]. With a view to detecting
those women at risk, objectifying endothelial function
and vascular function after healthy pregnancy and PE
can help to establish reference values for disturbed post-
pregnancy vascular function.
Methods/design
Study hypothesis
Endothelial and vascular function improve during healthy
pregnancy to answer the higher hemodynamic demands.
Due to the deficient placentation in PE, disturbed produc-
tion of (anti-) angiogenic and inflammatory factors results
in arterial stiffness and endothelial dysfunction. After PE,
this vascular dysfunction continues in patients at risk for
developing cardiovascular events later in life.
A certain amount of OS is necessary in healthy preg-
nancy. The deficient placental oxygenation in PE causes
excessive local formation of reactive oxygen and nitro-
gen species (O2•
− and •NO respectively). When the bal-
ance between pro-oxidant species and the antioxidants
is disturbed, OS arises. We hypothesize that in PE, there
is a higher amount of O2•
− in the maternal circulation
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and a lower concentration of •NO and eNOS measur-
able in the placenta.
Endothelial and vascular dysfunction is correlated to
the amount of OS present in the circulation.
Objectives
Primary study objective
To evaluate OS during pregnancy.
Measurement of •NO in placental tissue and O2•
− in
maternal blood using EPR.
Measurement of eNOS in placental tissue using
immuno-histochemical staining.
Prospective longitudinal study: To evaluate the OS
profile in normal pregnancies.
Matched case-control study: To compare the OS pro-
file in normal versus PE pregnancies.
Secondary study objectives
To evaluate endothelial function during pregnancy
(using peripheral arterial tonometry (PAT) and flow me-
diated dilatation (FMD) techniques) and to relate endo-
thelial function to •NO, O2•
− and eNOS concentration.
Prospective longitudinal study: To evaluate endothelial
function in normal pregnancies.
Matched case-control study: To compare endothelial
function in normal versus complicated pregnancies.
To evaluate arterial stiffness during pregnancy (Pulse
wave velocity, pulse wave analysis using Sphygmocor ®)
and to relate arterial stiffness to •NO, O2•
− and eNOS
concentration.
Prospective longitudinal study: To evaluate arterial
stiffness in normal pregnancies.
Matched case-control study: To compare arterial stiff-
ness in normal versus complicated pregnancies.
Methodology
Study design
Single centre prospective longitudinal study The first
part of the study will have a prospective longitudinal de-
sign. Pregnant women in their first trimester of preg-
nancy will be eligible and will be followed throughout
pregnancy and until 6 months postpartum.
Multicentre matched case-control study The second
part is a case control study where patients with pregnan-
cies complicated by PE will be compared to normoten-
sive controls, matched for maternal and gestational age,
parity, smoking behaviour, BMI and ethnic group. Pa-
tients will be followed throughout (the rest of their)
pregnancy and until 6 months postpartum. Matching
will reduce the risk of bias.
Study population
Inclusion criteria
1. Prospective longitudinal study
 Pregnant women ≥18 years old with a singleton
pregnancy
2. Matched case-control study
 Pregnant women ≥18 years old with a singleton
pregnancy and > 20 weeks of pregnancy
 Cases:
– Pre-eclampsia following the revised ISSHP definition
(2014) is [24]:
 Hypertension (> 140 mmHg systolic or > 90 mmHg
diastolic) developing after 20 weeks gestation and
the coexistence of one or more of the following new
onset conditions:
1. Proteinuria (spot urine protein/creatinine > 30 mg/
mmol [0.3 mg/mg] or > 300 mg/day or at least 1 g/L
[‘2 +’] on dipstick testing)
2. Other maternal organ dysfunction
– renal insufficiency (creatinine > 90 μmol/L)
– liver involvement (elevated transaminases – at
least twice upper limit of normal - and/or severe
right upper quadrant or epigastric pain)
– neurological complications (examples include
eclampsia, altered mental status, blindness,
stroke, or more commonly hyperreflexia when
accompanied by clonus, severe headaches when
accompanied by hyperreflexia, persistent visual
scotomata)
– hematological complications (thrombocytopenia:
platelet count below 150,000/dL, DIC, hemolysis)
3. Uteroplacental dysfunction: fetal growth restriction
Hypertension greater than or equal to 140 mmHg
systolic or 90 mmHg diastolic, must be confirmed at
least 4 h apart. Hypertension greater than or equal to
160 mmHg systolic or 110 mmHg diastolic can be
confirmed after a short interval (minutes) to facilitate
antihypertensive treatment [25].
Exclusion criteria Exclusion criteria are (gestational)
diabetes, multiple pregnancies, fetal abnormalities,
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hypercholesterolemia, renal disease, auto-immune disorders
and connective tissue disease. Intake of low-dose aspirin or
vitamin C supplements (> 500 mg/day) is an exclusion
criterion. Since in Belgium folic acid is an advised pre-
and periconceptional therapy, this will not act as an
exclusion criterion.
The use of other medication/supplements will be listed in
the patients record to find eventual confounders afterwards.
Description of investigations (scheme of investigations,
Fig. 1)
Endothelial function (FMD) The gold standard for non-
invasive assessment of endothelial function is FMD, meas-
uring NO-dependent vasodilation of the brachial artery in
response to reactive hyperaemia [26]. An ultrasound diag-
nostic instrument (Prosound alfa6, Hitachi Aloka Medical
®) equipped with vascular software for 2D-imaging, colour
Doppler imaging and ECG-triggering, are used with a high
frequency linear array transducer (UST-5413, 5-13 MHz,
Hitachi Aloka Medical ®). Patients are in a resting, supine
position with the arm in a comfortable position for im-
aging the brachial artery. A blood pressure cuff is placed
on the forearm with the upper border of the cuff at a dis-
tance of 5 to 10 cm distal from the elbow (lateral epicon-
dyle). The brachial artery is imaged above the antecubital
fossa in a longitudinal plane with a clear delineation of
both anterior and posterior intima-media interfaces. A
special probe-holding device is used to ensure consistency
of images during the measurement. The baseline artery
diameter is automatically tracked and the waveform of
diameter changes over the cardiac cycle is displayed in real
time using an automated edge detection system. (eTrack-
ing system, Aloka ®). Arterial occlusion is created by cuff
inflation to supra-systolic pressure at least 50 mmHg
above systolic pressure (minimum value of 200 mmHg)
for 5 min. Low–flow-mediated constriction (LFMC) is cal-
culated as the percent decrease in arterial diameter in the
last 30 s of cuff occlusion as compared with resting diam-
eter [27]. After 5 min of occlusion, the cuff is deflated.
Brachial diameter is recorded continuously (eTracking)
from the time point of cuff inflation to 5 min after cuff de-
flation. FMD (in % from baseline value) is expressed as
(post-ischemic maximal diastolic diameter change - base-
line diastolic diameter)/baseline diastolic diameter [26].
During the measurements, brachial artery blood
flows will be measured at 3 different time-points; at
rest, 15 s before cuff deflation, and immediately
upon cuff deflation using pulsed-wave Doppler [27].
All recordings are performed by two experienced in-
vestigators (IG, TS).
FMD and PAT measurements will be performed
simultaneously and patients will be asked 24 h prior
to examination not to eat high-fat substances nor
drink caffeine or alcohol and to refrain from smoking
at least 6 h prior to examination. Fingernails had to
be short and no nail polish applied. Patients were
studied in a quiet, temperature-controlled room (21-
24 °C) and stressful situations for the patient were
avoided (people entering the room unexpectedly, tele-
phone ringtones, etc.) Patients will not by measured
in active labour.
Fig. 1 Study design and key assessments. Study design and data collection overview. PI = pulsatility index; PP = postpartum; * Assessments at
moment of diagnosis; ** Laboratory parameters tested include NLR, MPV (mean platelet volume), platelet count, Fe, transferrin and ferritin
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Endothelial function (RHI) PAT is recorded using the
Endo-PAT2000® (Itamar Medical, software version 3.2.4)
and the disposable fingertip probes (Itamar Medical) in
accordance with the manufacturer’s recommendations.
PAT is a less operator-dependent and more reproducible
technique. The system uses pneumatic finger probes
which assess digital volume changes accompanying pulse
waves. Reactive hyperaemia is induced as described for
FMD and measurements are performed simultaneously to
FMD. The ratio of the average amplitude of the PAT signal
over a 1 min period starting 1 min after cuff deflation
(maximum pulse amplitude) divided by the average ampli-
tude of the PAT signal over a 3.5 min period before cuff
inflation (baseline pulse amplitude) is calculated. The con-
trol arm is used to correct for confounding factors (room
temperature, systemic changes). The result is expressed as
the reactive hyperaemia index (RHI) (Fig. 2). All record-
ings are performed simultaneously with the FMD and by
the same two experienced investigators (DM, EF).
Arterial stiffness: PWV, AP, AIx and AIx75 Pulse wave
velocity and pulse wave analysis will be calculated using
the Sphygmocor system ® (Atcor Medical, West Ryde,
Australia). To calculate PWV, two pressure waveforms
must be measured at a known distance apart and the dis-
tance between measurement sites is divided by the propa-
gation time. Aortic PWV is measured by carotid-femoral
PWV (cfPWV) as it is the ‘gold standard’ measurement of
the stiffness of the aorta. Measurements of cfPWV will be
performed using a pressure tonometer to transcutaneously
record the pressure pulse waveform in the underlying ar-
tery. The tonometer contains a micromanometer that pro-
vides a very accurate recording of the pressure within the
artery. The carotid and femoral PWV will be assessed by
gently compressing respectively the carotid artery and the
femoral artery with the tip of the tonometer at the site of
maximal pulsation. The Sphygmocor device will automat-
ically calculate the cfPWV.
Pulse wave analysis will calculate AIx by placing the
tonometer at the radial artery (site of maximum pulsa-
tion). A generalized transfer function will derive the aor-
tic pressure waveform from the radial artery waveform.
From the aortic pressure waveform, the augmentation
pressure (AP) and augmentation index (AIx) can be cal-
culated. The AP (ΔP) is defined as the height of the late
systolic peak above the inflection point on the waveform.
The AIx is defined as AP expressed as a percentage of
the aortic PP. As AIx is affected by heartrate, it will be
standardized to a heart rate of 75 bmp (AIx-75).
Pulsatility index uterine artery and fetal biometry
Uterine artery Doppler examinations will be performed
using trans-abdominal colour directed pulsed wave Dop-
pler (Voluson, GE Healthcare Technologies, USA). Pul-
satility index of both uterine arteries will be obtained on
either side of the cervix before 14 weeks’ gestation and
at the apparent crossover with the external iliac arteries
after 14 weeks [28, 29].
Three similar consecutive waveforms must be obtained
before calculating the PI. The mean PI of the two vessels
was calculated. Observation on the presence or absence of
a bilateral early protodiastolic notch will be performed. A
notch is defined as a persistent decrease in blood flow vel-
ocity below the diastolic peak velocity, in early diastole.
At the same moment basic fetal biometry parameters
will be measured: bi-parietal diameter, head circumfer-
ence, abdominal circumference, femur length and ex-
pected fetal weight using Hadlocks formula [30].
Fig. 2 Representative reactive hyperaemia peripheral arterial tonometry recordings of subjects with normal and abnormal reactive hyperaemic
response. Normal response is characterized by a distinct increase in the signal amplitude after cuff release compared with baseline
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Markers of systemic inflammation Performing a
complete blood count (CBC), the neutrophil/lymphocyte
ratio (NLR), mean platelet volume (MPV) and platelet
count will be obtained using a ADVIA 120 Hematology
System (Siemens healthcare, Germany) [31–33].
Automated blood pressure measurement SBP, DBP
and MAP after 10 min rest in a sitting position, will be mea-
sured using a Mindray VS 900 monitor (Mindray ®, China).
Oxidative stress
Electron paramagnetic resonance EPR (electron para-
magnetic resonance) is derived from magnetic resonance
spectroscopy and uses microwave radiation to detect
molecules with an unpaired electron number, like radi-
cals. When an magnetic field is created by the EPR spec-
trometer, all radicals will align. The EPR spectrometer
sends out a radio frequent microwave, causing the elec-
trons to jump from a low to a high energy state. This en-
ergy absorption can be measured and is directly
correlated to the amount of free radicals in the sample.
A ‘spin trap’ will be added to scavenge the very reactive
radicals and to prolong their half live. EPR spectra will
be obtained using the Bruker EMX 1273 spectrometer
equipped with an ER 4119HS high-sensitivity resonator
(=cavity) and 12-kW power supply operating at X band
frequencies. The Bruker WINEPR -post processing sys-
tem software (Germany, 1996) will be used to analyse
the spectra [34].
Placental concentration of •NO Placental tissue will be
obtained within 2 min after (vaginal or caesarean) delivery.
At a standardized central location, a viable sample of
1cm3 placental tissue will be taken avoiding placental in-
farcts. The sample will be rinsed with saline (NaCl) and
immediately added to the spin trap 750 μl FeSO4 + 750 μl
DETC (iron (II) diethyldithiocarbamate solution). After
1 h of incubation at 37 °C, the sample will be snap frozen
and stored in − 80 °C until analysis with EPR [34].
Since labour causes ischemia-reperfusion injury at the
site of the placenta, which will influence placental NO
concentrations, samples will be subdivided in labour (va-
ginal delivery, secondary caesarean section) versus no
labour (elective caesarean section) [35].
Maternal blood concentration of O2•
− Maternal blood
will be obtained at 12 weeks and 24-28 weeks in a heparin
tube (BD vacutainer) and transported on ice. After
15 min, 30 μl of spin trap CMH (1-hydroxy-3-methoxy-
carbonyl-2,2,5,5-tetramethylpyrrolidine) will be added to
30 μl blood. The whole will be incubated on ice and trans-
ferred into a capillary after 5 min. The sample will then be
snap frozen and stored in − 80 °C until analysis [34].
Immuno-histochemical staining for eNOS and iNOS
Placental tissue will be obtained shortly after delivery
and stained for eNOS and iNOS as previously described
by Du et al. [36]
Statistical methods
Sample size calculations
As sample size determining factor, we took the RHI
since this is an important variable in our study, there
is normal distribution and the population standard
deviation is known.
Prospective longitudinal study For the physiologic
study of the RHI in pregnancy we calculate that for a
95% confidence interval, a population standard deviation
of 0.5 (as described in other populations for RHI) and a
tolerable standard error of the mean (SEM) value of 0.1,
97 women have to be followed [37]. Taking at least a
10% dropout into account the starting sample size will
be 110 women.
Matched case-control study In a pilot study by Yinon
[38] the RHI in normotensive pregnancies was 1.8, and in
PE 1.5; in most populations standard deviation is 0.5 [37].
For 80% power and a two sided α = 0.05 and considering a
0.3 difference clinically relevant, the sample size for each
group would be 44 (http://www.stat.ubc.ca/~rollin/stats/
ssize/n2.html); which we consider the sample size for our
cross-sectional study comparing pre-eclamptic patients
with normotensive controls. The sample size of this study
will be 90 patients, 45 in each group.
Descriptive statistics and data analysis
Prospective longitudinal study For the physiologic study
of the RHI in pregnancy we will calculate the reference
values and 95% confidence interval. Longitudinal data will
be plotted and a linear mixed-effects model with random
intercept will be fitted. Percentiles for RHI, FMD and
PWV/PWA will be calculated based on this model. Correl-
ation coefficients between baseline RHI, FMD PWV/PWA,
UA Doppler PI, fetal biometry, NLR, MPV, MAP, birth-
weight percentile, eNOS, •NO and O2•
− will be analysed.
Matched case-control study RHI, FMD, PWV/PWA,
UA Doppler PI, fetal biometry, NLR, MPV, MAP, birth-
weight, eNOS, •NO and O2•
− concentration and other
continuous variables in PE versus healthy pregnancies
will be tested for normality using the Shapiro Wilk Test.
If there is normality, they will be expressed as mean,
standard deviations and 95% confidence intervals and
compared using two sided T test. If not, they will be
expressed as median and interquartile ranges and com-
pared using Mann Whitney U Test.
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Discussion
PE is responsible for 11.5% of maternal deaths in Flan-
ders. Ten percent of early neonatal deaths are caused by
maternal hypertensive disorders [39]. This project will
contribute to the knowledge of PE with the ultimate goal
of reducing maternal morbidity and mortality.
As stated before, the gold standard for non-invasive
assessment of endothelial function is FMD [26]. Previous
literature suggests that during normal pregnancy, there
is a steady increase in FMD until week 32, with a
stabilization or even decline at week 36 [40]. In PE, a
significant reduction in FMD is suggested [41]. Data
using PAT during pregnancy and PE are limited, based
on small studies and they show opposing results [38,
42]. Due to measurement of peripheral microcirculatory
function, PAT is less NO-dependent than FMD. As such,
FMD and PAT assess different aspects of vascular func-
tion [43–45]. Arterial stiffness has been evaluated in
pregnancy, using applanation tonometry (AP) [2]. Dur-
ing normal pregnancy AIx falls during mid pregnancy
and rises at the end of pregnancy. In PE AIx is signifi-
cantly increased and a significant role of first trimester
AIx in the early screening of PE has been proposed [2].
Arterial stiffness is independently associated with cardio-
vascular risk and may, therefore, provide a potential
marker to select women who will develop cardiovascular
events later in life after PE [2, 46]. Concerning endothe-
lial function and arterial stiffness in normal pregnancy
and PE there is still no consent in literature and further
research is warranted.
Both in normal pregnancy and PE are inflammatory ef-
fects present, which can be objectified by higher neutrophil
to lymphocyte ratio (NLR) and higher mean platelet vol-
ume (MPV) [47]. Increase in NLR and MPV are described
to be more prominent in PE, and these factors have been
proposed as predictive biomarkers for PE [31, 48]. In-
creased systemic low grade inflammation possibly contrib-
utes to alterations in endothelial function.
Previous research has demonstrated that markers of
OS, like O2•
−, hydrogen peroxide (H2O2), hydroxyl rad-
ical (•OH), nitric oxide (•NO), and peroxynitrite
(ONOO−) are involved in the pathophysiology of placen-
tal pregnancy disorders. OS at the site of the placenta
causes placental damage and this ischemic placenta re-
leases cytotoxic, anti-angiogenic and inflammatory
markers in the circulation resulting in systemic endothe-
lial dysfunction and peripheral organ damage [3]. O2•
−,
the most abundant free radical, encloses an important
role in the beneficial effects of OS. Studies measuring
O2•
− concentration longitudinally in normal pregnancy
and during PE are lacking, creating a gap in the know-
ledge of OS in pregnancy and PE. Evidence for OS at the
placenta and in the maternal circulation in PE has led to
the suggestion that anti-oxidant therapy can improve or
even prevent PE. Vitamins E and C, L-arginine (precur-
sor of •NO) and •NO donors have been proposed to
limit both endothelial injury and for the prevention of
PE with conflicting results [49–55]. Substantial know-
ledge of the evolution of OS in healthy and PE pregnan-
cies might influence introduction of these therapies in
regular medical practice.
ENDOPREG is the first clinical study comparing in
vivo measurements of endothelial function with in vitro
markers of endothelial dysfunction in a longitudinal and
case-control setting. To our knowledge, serial changes in
maternal endothelial function have not been evaluated
previously in pregnancy using two different methods, i.e.
PAT/FMD and EPR, simultaneously. The main strength
of our study is the longitudinal design. Little studies de-
termined maternal •NO or reactive oxygen species con-
centration at the moment of diagnosis [56] and only a
few performed a longitudinal approach. Studying endo-
thelial function and OS profile in and after normal preg-
nancies and PE, will give a better insight in the
pathophysiology of this pregnancy complication and will
help with the detection of patients a risk of developing
cardiovascular events later in life. Within the ENDO-
PREG study, research groups from biomedical and
pharmaceutical sciences will collaborate to unravel yet
another step in the pathophysiology of the disease of
many theories, PE.
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